A Phase Ib Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Their Standard Treatment
Latest Information Update: 10 Jun 2020
At a glance
- Drugs Venetoclax (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 31 May 2020 Results from NCT02755597, NCT01794520, NCT01794507, NCT02899052 and 1 retrospective study evaluating advances in precision therapy with venetoclax in multiple myeloma with and high BCL2 expression, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 19 Mar 2019 According to an AbbVie media release, the company announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials evaluating venetoclax for the investigational treatment of multiple myeloma. The partial clinical hold follows a review of data from BELLINI study.As a result of this action, no new patients should be enrolled in any studies of venetoclax for multiple myeloma until a further analysis of the data is completed.
- 19 Mar 2019 Planned End Date changed from 3 Jan 2019 to 29 Mar 2019.